Smith & Nephew SNATS (NYSE:SNN) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Smith & Nephew SNATS (NYSE:SNN) from a strong-buy rating to a buy rating in a research report report published on Friday.

A number of other research analysts also recently issued reports on SNN. Canaccord Genuity Group boosted their price objective on Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a “hold” rating in a research note on Monday, August 18th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Saturday, September 27th. Seven analysts have rated the stock with a Hold rating, According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $36.00.

Smith & Nephew SNATS Stock Performance

Shares of SNN opened at $36.34 on Friday. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The business has a 50-day simple moving average of $36.16 and a two-hundred day simple moving average of $31.23. The stock has a market cap of $15.83 billion, a price-to-earnings ratio of 16.83, a PEG ratio of 1.00 and a beta of 0.69. Smith & Nephew SNATS has a 52 week low of $23.69 and a 52 week high of $38.79.

Smith & Nephew SNATS Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be given a dividend of $0.285 per share. The ex-dividend date is Friday, October 3rd. This represents a dividend yield of 165.0%. Smith & Nephew SNATS’s dividend payout ratio (DPR) is presently 26.39%.

Hedge Funds Weigh In On Smith & Nephew SNATS

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of Montreal Can increased its holdings in Smith & Nephew SNATS by 321.6% in the 2nd quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock valued at $105,056,000 after acquiring an additional 2,616,301 shares during the last quarter. River Road Asset Management LLC grew its position in shares of Smith & Nephew SNATS by 9.3% during the second quarter. River Road Asset Management LLC now owns 3,179,814 shares of the medical equipment provider’s stock valued at $97,175,000 after purchasing an additional 270,480 shares in the last quarter. Scharf Investments LLC grew its position in shares of Smith & Nephew SNATS by 0.3% during the second quarter. Scharf Investments LLC now owns 2,083,513 shares of the medical equipment provider’s stock valued at $63,818,000 after purchasing an additional 6,993 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Smith & Nephew SNATS by 49.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after purchasing an additional 583,809 shares during the last quarter. Finally, Armistice Capital LLC lifted its position in shares of Smith & Nephew SNATS by 258.1% in the first quarter. Armistice Capital LLC now owns 1,769,000 shares of the medical equipment provider’s stock worth $50,187,000 after buying an additional 1,275,000 shares in the last quarter. Institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.